Hello [[INITIATIVE.AUDIENCE MEMBER.FIRST NAME]],
We are proud to announce that Sarah Schiltz, a Blue Faery Board Director, has been named in Cancer Health’s prestigious Cancer Health 25 list — a national salute to individuals who are making a powerful impact in the cancer community.
This prestigious accolade highlights leaders across the U.S. who are driving meaningful change: providing patient support, bridging gaps in care, elevating marginalized voices, and shaping a more inclusive cancer community. Sarah exemplifies our mission — guiding patients and caregivers through the complexities of hepatocellular carcinoma (HCC) with empathy and expertise.
At Blue Faery, we’re driven by one core belief: no one should face liver cancer alone. Sarah’s recognition is not only a personal achievement but a win for everyone affected by liver cancer. Her commitment, insight, and leadership help fuel our programs — from direct patient support in our Liver Cancer Community to national educational efforts like Love Your Liver.
Please join us in congratulating Sarah on this well-deserved honor. We are grateful for her voice, her vision, and her heart. Thank you for being part of this journey.
Fighting Liver Cancer Together Andrea Wilson Woods Founder and President |
|
|
In this workshop, liver cancer caregivers Cathy Anderson, Azure Klein, and Karen Wright and many others will share their stories about caring for a loved one with liver cancer. A Q&A session will follow. This event is perfect for liver cancer patients, caregivers, providers, or anyone interested in learning more about liver cancer care. |
|
|
Blue Faery is hosting an HCC Lunch & Learn in Dallas on Saturday, September 27. Working with physicians from UT Southwestern, this in-person program provides at-risk communities with critical education about liver health, liver disease, and liver cancer. There will be a free catered lunch and light breakfast snacks. |
If you live in the Dallas area, love meeting new people, and want to learn more about preventing liver disease and cancer, we are seeking four volunteers for the day. |
You and Liver Cancer 2025
|
In collaboration with Mechanisms in Medicine Inc., Blue Faery designed You and Liver Cancer to meet the educational needs of patients and caregivers affected by liver cancer. With Animations, Slideshows, Expert Videos, Patient Stories, Infographics, and a Survey, the program impacted over 15,000 individuals during its first year.
For 2025, we have three new modules: ▶️ Clinical Trials in Liver Cancer ▶️ Liver Cancer Surgery and Transplant ▶️ Fatty Liver Disease and HCC
We are still seeking a person with HCC who has participated in a clinical trial to share their story. If you're interested, please email our new program manager Aura Sanchez. Special thanks to our You and Liver Cancer sponsors: AstraZeneca, Eisai, Exelixis, Genentech, and Merck. |
|
|
In order from newest to oldest |
-
AstraZeneca’s A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination with Durvalumab and Bevacizumab Therapy in People with Unresectable Hepatocellular Carcinoma Amenable to TARE*
-
Boston Scientific’s A global, open-label, multi-center, phase II, single-arm study to assess the efficacy of TheraSphere Y-90 Glass Microspheres TARE procedure followed by Durvalumab (Imfinzi®) with Tremelimumab (Imjudo®) (STRIDE regimen) in patients with hepatocellular carcinoma (ROWAN)*
-
Genentech’s A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Patients With Unresectable Hepatocellular Carcinoma and Child-Pugh B7 and B8 Cirrhosis (Kirros)*
-
Mayo Clinic’s Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer*
-
Genentech’s A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)*
-
Eureka Therapeutics’ ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2)*
-
Eureka Therapeutics’ An Open-Label, Dose-Escalation, Multi-Center Phase I/II Clinical Trial of ECT204 T-Cell Therapy in Adults with Advanced Hepatocellular Carcinoma (HCC)*
-
Mayo Clinic’s Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar
|
*Indicates a paid listing. If your trial is no longer recruiting, please email George right away. |
|
|
Questions? Email us at info@bluefaery.org. No longer want to hear from us? Just unsubscribe.
© 2024 – 2025 Blue Faery. All rights reserved. Blue Faery | 2828 Cochran St Ste 176 | Simi Valley, CA 93065
|
|
|
|